Brokerage Firm Rating Update on Gilead Sciences (GILD)

Gilead Sciences (GILD) : Zacks Investment Research ranks Gilead Sciences (GILD) as 4, which is a Sell recommendation. 9 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. A total of 8 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 18 research analysts is 1.94, which indicates as a Buy.

Gilead Sciences (GILD) : Average target price received by Gilead Sciences (GILD) is $108.75 with an expected standard deviation of $9.16. The most aggressive target on the stock is $122, whereas the most downbeat target is $91. 12 financial analysts are currently covering the stock.


For the current week, the company shares have a recommendation consensus of Buy. Also, Equity analysts at the Brokerage firm Jefferies maintains its rating on Gilead Sciences (NASDAQ:GILD). The rating major has initiated the coverage with hold rating on the shares. The Analysts at Jefferies lowers the price target from $93 per share to $91 per share. The rating by the firm was issued on August 31, 2016.

Gilead Sciences (NASDAQ:GILD): The stock opened at $78.38 and touched an intraday high of $78.805 on Wednesday. During the day, the stock corrected to an intraday low of $77.92, however, the bulls stepped in and pushed the price higher to close in the green at $78.22 with a gain of 0.44% for the day. The total traded volume for the day was 8,232,697. The stock had closed at $77.88 in the previous trading session.

Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.